The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
- Author
- ReachMD
- Published
- Mon 30 Dec 2024
- Episode Link
- http://reachmd.com/programs/cme/the-role-of-biomarker-driven-therapies-in-the-second-line-treatment-of-advanced-gastricgej-cancers-what-do-the-data-say/29847/
CME credits: 1.25
Valid until: 30-12-2025
Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-biomarker-driven-therapies-in-the-second-line-treatment-of-advanced-gastricgej-cancers-what-do-the-data-say/29847/
Valid until: 30-12-2025
Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-biomarker-driven-therapies-in-the-second-line-treatment-of-advanced-gastricgej-cancers-what-do-the-data-say/29847/
The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updated as new therapies are approved or as drugs received expanded indications. Moreover, data are constantly evolving regarding the role of biomarkers and treatment choice. This activity has been designed to provide an overview of the NCCN guidelines for gastric, colorectal, and hepatocellular cancers and the optimal application of these recommendations to clinical practice.
